Human Phospho-M-CSF R/CD115 (Y723) Antibody
R&D Systems, part of Bio-Techne | Catalog # AF3268
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Key Product Details
Validated by
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Specificity
Clonality
Host
Isotype
Scientific Data Images for Human Phospho-M-CSF R/CD115 (Y723) Antibody
Detection of Human Phospho-M-CSF R/CD115 (Y723) by Western Blot.
Western blot shows lysates of M-CSF R/CD115-transfected NS0 mouse myeloma cell line untreated (-) or treated (+) with 100 ng/mL Recombinant Human M-CSF/CD115 (Catalog # 216-MC) for 10 minutes. PVDF membrane was probed with 0.5 µg/mL of Rabbit Anti-Human Phospho-M-CSF R/CD115 (Y723) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3268), followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for Phospho-M-CSF R/CD115 (Y723) at approximately 175 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.M-CSF R/CD115 in Human PBMCs.
M-CSF R/CD115 phosphorylated at Y723 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Rabbit Anti-Human Phospho-M-CSF R/CD115 (Y723) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3268) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rabbit IgG Secondary Antibody (red; Catalog # NL004) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.Applications for Human Phospho-M-CSF R/CD115 (Y723) Antibody
Immunocytochemistry
Sample: Immersion fixed human peripheral blood mononuclear cells
Western Blot
Sample: M‑CSF R‑transfected NS0 mouse myeloma cell line treated with Recombinant Human M‑CSF/CD115 (Catalog # 216-MC)
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: M-CSF R/CD115
M-CSF R, the product of the c-fms proto-oncogene, is a member of the type III subfamily of receptor tyrosine kinases that also includes receptors for SCF and PDGF. These receptors each contain five immunoglobulin-like domains in their extracellular domain (ECD) and a split kinase domain in their intracellular region (1‑4). M-CSF R is expressed primarily on cells of the monocyte/macrophage lineage, dendritic cells, stem cells and in the developing placenta (1). Human M-CSF R cDNA encodes a 972 amino acid (aa) type I membrane protein with a 19 aa signal peptide, a 493 aa extracellular region containing the ligand-binding domain, a 25 aa transmembrane domain and a 435 aa cytoplasmic domain. The human M-CSF R ECD shares 60%, 64%, 72%, 75%, 75% and 76% aa identity with mouse, rat, bovine, canine, feline and equine M-CSF R, respectively. Activators of protein kinase C induce TACE/ADAM17 cleavage of the M-CSF R, releasing the functional
ligand-binding extracellular domain (5). M-CSF binding induces receptor homodimerization, resulting in transphosphorylation of specific cytoplasmic tyrosine residues and signal transduction (6). The intracellular domain of activated M-CSF R binds more than 150 proteins that affect cell proliferation, survival, differentiation and cytoskeletal reorganization. Among these, PI3Kinase, P42/44 ERK and c-Cbl are key transducers of M-CSF R signals (3, 4). M-CSF R engagement is continuously required for macrophage survival and regulates lineage decisions and maturation of monocytes, macrophages, osteoclasts and DC (3, 4). M-CSF R and integrin alphav beta3 share signaling pathways during osteoclastogenesis and deletion of either causes osteopetrosis (7, 8). In the brain, microglia expressing increased M-CSF R are concentrated with Alzheimers a beta peptide, but their role in pathogenesis is unclear (9, 10).
References
- deParseval, N. et al. (1993) Nucleic Acids Res. 21:750.
- Rothwell, V.M. and L.R. Rohrschneider (1987) Oncogene Res. 1:311.
- Chitu, V. and E.R. Stanley (2006) Curr. Opin. Immunol. 18:39.
- Ross, F.P. and S.L. Teitelbaum (2005) Immunol. Rev. 208:88.
- Rovida, E. et al. (2001) J. Immunol. 166:1583.
- Yeung, Y. et al. (1998) J. Biol. Chem. 273:17128.
- Dai, X. et al. (2002) Blood 99:111.
- Faccio, R. et al. (2003) J. Clin. Invest. 111:749.
- Li, M. et al. (2004) J. Neurochem. 91:623.
- Mitrasinovic, O.M. et al. (2005) J. Neurosci. 25:4442.
Long Name
Alternate Names
Gene Symbol
Additional M-CSF R/CD115 Products
Product Documents for Human Phospho-M-CSF R/CD115 (Y723) Antibody
Product Specific Notices for Human Phospho-M-CSF R/CD115 (Y723) Antibody
For research use only